Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 10Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Urinary Bladder Neoplasms 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Metastatic Urothelial Cell Cancer 1Melanoma 1Lymphoma 1Lung Neoplasms 1Inflammatory Breast Neoplasms 1HER-2 Positive Breast Cancer 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Trastuzumab 3Taxes 3Radiotherapy 3Paclitaxel 3Cyclophosphamide 3Epirubicin 2Doxorubicin 2Docetaxel 2Biopsy 2trastuzumab biosimilar HLX02 1talimogene laherparepvec 1romidepsin 1pertuzumab 1pembrolizumab 1pegfilgrastim 1nintedanib 1neratinib 1grapiprant 1eribulin 1caficrestat 1bemcentinib 1Tamoxifen 1Razoxane 1Radiation 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1Neoadjuvant Therapy 1Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Inflammatory Breast Neoplasms × eribulin × Clear all
NCT05041101 2025-06-13

Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
6 enrolled 11 charts
Breast

Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡